

LIDDS: Interview with CEO Monica Wallter

## Redeye Research Note

2021-04-15

Redeye interviewed Monica Wallter during her last days as CEO of LIDDS. We discussed how the company has transformed under her leadership and the road ahead.



*Monica, you have served as the CEO of LIDDS since 2015. How would you summarise your time at the company and the most significant achievements?*

One of the most important strategic steps I took was to transform LIDDS from a one-project startup to a technology platform company with the aim to develop intratumoral sustained-release products within the area of oncology. The technology was branded as NanoZolid® with trademark registrations both in the USA and in Europe.

We extended the patent protection of the NanoZolid portfolio with another ten years as new patents were granted until 2037. LIDDS has also progress in the clinic: we have two projects in clinical development and another phase I study with a TLR9- agonist is planned to start later this year. In addition, there are very exciting oncology projects in the feasibility phase that are not yet disclosed to the market.

Finally, we have proven that we are capable of collaborating and out-licensing with the recent R&D agreement with Johnson & Johnson and with the out-license agreement for prostate cancer drug candidate Liproca Depot to a Chinese partner.

*LIDDS has now several very interesting projects and has entered a research agreement with J&J, how would you describe the potential of the company going forward?*

LIDDS' strategy is to treat cancer directly in the tumour to enhance efficacy and limit the severe side effects of systemic oncology treatments. It also addresses many of the challenges of recently introduced oncology treatments and can be complementary to them. It is a breakthrough for LIDDS that J&J, one of the world's largest pharma companies, is very interested in developing oncology products based on the NanoZolid technology! Of course it also potentially validates LIDDS as a key player in the local and intratumoural cancer treatment. It will be very exciting to follow this collaboration, along with LIDDS' own projects with various targets.

*Lets talk about leadership. What kind of a leader are you?*

Well, I would probably be regarded as an enthusiastic leader, who strives to support change and development. I am teamwork-oriented and am acting as a coach both in operational and senior advisory roles.

*What kind of company are you passing on, as compared to the company you took over? How has LIDDS transformed under your leadership?*

LIDDS has developed from a research organisation into a company with clinical development and collaboration capability. It has a senior and experienced organization to meet the demand from in-licensing pharma companies, to handle preclinical- and clinical studies, GMP manufacturing and patent strategy. LIDDS will also apply to be listed at the Nasdaq Main Market. The company has also prepared to meet the higher demands on transparency from Nasdaq, taking steps to strengthen the investors base.

*You will be serving in a new role as an adviser to LIDDS, any new initiatives that you will be spending time on in the future?*

Yes, I will remain in LIDDS as Senior Advisor and will also use my business and marketing experience from big pharma & biotech companies to take on other consultancy or Board of Director roles.

*Thank you for being with us today and we wish you good luck in your new initiatives!*



Gergana Almquist

Equity Analyst